---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-004772"
form_type: "8-K/A"
ticker: "CNSP"
cik: "0001729427"
company_name: "CNS Pharmaceuticals, Inc."
filed_at: "2024-07-12T23:59:59+00:00"
generated_at: "2026-05-31T21:11:08.734437+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# CNS Pharma regains Nasdaq bid price compliance; still faces equity rule delisting risk

## Summary
- Received Nasdaq letter on July 5, 2024 confirming bid price compliance (closing bid >=$1.00 for 20 consecutive business days through July 3).
- Previously granted extension until July 15, 2024 to demonstrate compliance with both Bid Price and Equity Rules.
- Company still not compliant with $2,500,000 stockholders' equity requirement (Nasdaq Listing Rule 5550(b)); further updates expected.
- Delisting risk remains if equity compliance not demonstrated by deadline.

## SEC filing metadata
- accession: 0001683168-24-004772
- form_type: 8-K/A
- ticker: CNSP
- cik: 0001729427
- company_name: CNS Pharmaceuticals, Inc.
- filed_at: 2024-07-12T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1729427/000168316824004772/0001683168-24-004772-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1729427/000168316824004772/cns_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-004772
- JSON: https://secwatch.observer/filing/0001683168-24-004772.json
- Plain text: https://secwatch.observer/filing/0001683168-24-004772.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.